World's oldest boomerang doesn't actually come back
The world's oldest boomerang is older than previously thought, casting new light on the ingenuity of humans living at the time.
The tool, which was found in a cave in Poland in 1985, is now thought to be 40,000 years old.
Archaeologists say it was fashioned from a mammoth's tusk with an astonishing level of skill.
Researchers worked out from its shape that it would have flown when thrown, but would not have come back to the thrower.
It was probably used in hunting, though it might have had cultural or artistic value, perhaps being used in some kind of ritual.
The mammoth ivory boomerang was unearthed in Oblazowa Cave in southern Poland.
It was originally thought to be about 30,000 years old. But new, more reliable radiocarbon dating of human and animal bones found at the site puts the age at between 39,000 and 42,000 years old.
"It's the oldest boomerang in the world, and the only one in the world made of this shape and this long to be found in Poland," said Dr Sahra Talamo of the University of Bologna, Italy.
It gives a "remarkable insight" into human behaviour, she said, particularly how Homo sapiens living as long as 42,000 years ago could shape "such a perfect object" with the knowledge it could be used to hunt animals.
The boomerang is exceptionally well preserved, with score marks suggesting it had been polished and carved for use by a right-handed individual.
Boomerangs are generally associated with Aboriginal culture in Australia.
However, rare finds in the historical record outside Australia suggest they were used across different continents.
The oldest known boomerang from Australia dates to about 10,500 years ago, made from wood. But the oldest images of boomerangs in Australia are rock art paintings 20,000 years old, according to National Museum Australia.
A wooden boomerang dating back 7,000 years has been found in Jutland, a peninsula between Denmark and Germany, while fragments of a 2,000-year-old oak boomerang – which does come back – has been found in The Netherlands.
The research by a team of scientists from Poland, Italy, Germany, France, Switzerland and the UK is published in the journal PLOS One.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
an hour ago
- CBS News
How AI is helping unravel mystery of ancient scrolls buried in Mount Vesuvius eruption
AI is helping to solve an ancient mystery involving Mount Vesuvius. Here's how. Artificial intelligence is helping to solve an ancient mystery from the Roman Empire involving scrolls from a library that was buried when Mount Vesuvius erupted. The eruption of Vesuvius in A.D. 79 not only wiped out Pompeii, but also the nearby town of Herculaneum. Deep beneath the surface where a villa previously existed, archaeologists in the 18th century found 1,800 papyrus scrolls in the only ancient library in the world that is still intact. Attempts to unravel some of the scrolls ended in ashes as the library was carbonized, Brent Seales, a computer scientist from the University of Kentucky, explained. "People didn't understand what they had. So, some scrolls were actually thrown away or burned and you can't put Humpty Dumpty back together again," Seales said. Archaeologists in the 18th century found papyrus scrolls in the only ancient library in the world that is still intact. CBS News But thanks to 21st-century technology, experts are now able to examine those still intact. That technology involved a particle accelerator in England. Scientists produced light that was 10 billion times brighter than the sun, much like an X-ray. AI was then used to identify ink, no matter how faint. "I thought to myself, if you can use that technology to see non-invasively inside a human body, why can't we see everything inside an artifact like a scroll?" Seales said. Deciphering the scroll They still needed humans to decipher what the letters mean. So Seales launched the Vesuvius Challenge, a global competition offering $700,000 in prize money. Three college students took it home, making history by being the first to extract words from a carbonized scroll, nearly 2,000 years old, that had been virtually unwrapped. Thanks to new technology, experts can examine the scrolls still intact. CBS News With hundreds more scrolls to go, Seales has launched a second phase of the competition. "With AI-inspired methods that are going to usher in, you know, new results that we've not dreamed of, I don't think renaissance is too strong a word," he said. Seales said he believes there could be more scrolls out there as archaeologists are just beginning to scratch the surface. "I believe the Villa of the Papyri, which has not been fully excavated, stands a really high chance of producing more books," he said. "So much remains for us to discover."
Medscape
3 hours ago
- Medscape
Novel Herbal Emollients Plus Benefit Patients With AD
TOPLINE: A novel herbal emollient plus combination containing ginger extract and cannabidiol was effective and provided sustained relief of itch, progressive improvement of objective symptoms, and stabilisation of the skin barrier in patients with atopic dermatitis (AD) over a period of 12 weeks. METHODOLOGY: Researchers analysed 94 adults and children with AD (adults ≥ 18 years; children < 18 years) in a 12-week prospective interventional monocentric trial. Participants applied BNO 3732 body lotion twice daily and BNO 3731 intensive care product as needed. Both products contained ginger extract and cannabidiol as active cosmetic ingredients. Researchers evaluated outcomes using the peak pruritus numerical rating scale, Recap of atopic eczema (RECAP), Dermatology Quality of Life Index (DLQI), children's DLQI (CDLQI), and validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD). In adult subgroups, researchers assessed the epidermal barrier integrity via intercellular lipid levels, lamellar organisation, and corneocyte maturity. TAKEAWAY: A significant improvement was observed in mean RECAP sum scores (P < .001), with a 54% reduction seen in the first 4 weeks, and peak pruritus significantly decreased by 53% after 4 weeks (P < .001); the outcomes were sustained over 12 weeks. Mean vIGA-AD scores decreased by 63% over 12 weeks, with 88% of participants classified as responders and 59% achieved clearance by week 12. The skin-related quality of life for adults and children (4-15 years) significantly increased in the first 4 weeks according to the DLQI and CDLQI, respectively, followed by a progressive improvement over the remaining 8 weeks. An instrumental analysis revealed significant increases in ceramide EOS, ceramide NP, free fatty acids, and cholesterol contents after 12 weeks of product application (P ≤ .05). The mean length of lipid lamellae significantly increased from 61.08 to 196.23 nm/1000 nm2 (P < .001), reaching levels comparable with those of the healthy skin. The ratio of mature to immature corneocytes was significantly increased after 12 weeks (P < .001), indicating enhanced barrier integrity. IN PRACTICE: "Oil-in-water emulsions BNO 3732 and BNO 3731 containing the ACIs [active cosmetic ingredients] ginger extract and cannabidiol with anti-inflammatory and antioxidative in vitroactivities are efficacious beyond mere moisturizing and occlusive properties by providing sustained relief of itch, long-lasting improvement of objective AD symptoms, and stabilization of the epidermal permeability barrier," the authors of the study wrote. SOURCE: This study was led by Lars Herrmann, Bionorica SE, Neumarkt, Germany. It was published online on June 18, 2025, in Acta Dermato-Venereologica. LIMITATIONS: This study had several limitations, including the absence of a dedicated control group. Additionally, the subpanel for instrumental skin barrier analysis was reduced compared to the complete study population. The researchers also noted that no instructions were available regarding the amount of products to be used, preventing the correlation analysis between the magnitude of effects and product usage amounts. DISCLOSURES: This study was funded by Bionorica SE in Neumarkt in der Oberpfalz, Germany. Eight authors reported being employees of Bionorica SE. One author is named as an inventor on a patent application for compositions containing cannabidiol and an extract from ginger. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
4 hours ago
- Medscape
Cardiovascular Risk Not Key in Presurgical Med Management
TOPLINE: The STOP-or-NOT study of patients undergoing major noncardiac surgery found no difference in the postoperative risk for death or major complications in those who continued or discontinued treatment with renin-angiotensin system inhibitors (RASi) prior to the procedure. A new post hoc analysis of the randomized controlled trial found stratification of preoperative cardiovascular risk does not affect patient outcomes for the strategy, either. METHODOLOGY: Researchers conducted a post hoc analysis of the multicenter STOP-or-NOT randomized clinical trial, which included patients at 40 hospitals in France between January 2018 and April 2023, with a 28-day postoperative follow-up. Participants included 2222 patients (median age, 68 years, 35% women) who had been treated with RASi agents for at least 3 months before undergoing major noncardiac surgery. Patients were randomly assigned to either continue taking their RASi until the day of surgery or discontinue the medication 48 hours before the procedure. Primary outcome measures were a composite of all-cause mortality and major postoperative complications. Secondary outcomes included major cardiovascular events and acute kidney injury. The researchers used the Revised Cardiac Risk Index (RCRI), the American University of Beirut-HAS2 Cardiovascular Risk Index, and systolic blood pressure prior to randomization to assess cardiovascular risk. TAKEAWAY: Using the RCRI, 592 patients were categorized as low risk, 1095 as intermediate-low risk, 418 as intermediate-high risk, and 117 as high risk. The American University of Beirut-HAS2 score categorized 1049 patients as low risk, 727 as intermediate-low risk, 333 as intermediate-high risk, and 113 as high risk. While the risk for postoperative complications and major cardiovascular events varied with a person's score on the RCRI, continuing or discontinuing RASi was not associated with an increased risk for surgical complications. IN PRACTICE: 'This study found that preoperative cardiovascular risk did not affect patient outcomes with respect to the strategy of continuing vs discontinuing RASi before major noncardiac surgery, suggesting that the decision to continue or discontinue RASi should not be influenced by a patient's preoperative cardiovascular risk assessment,' the researchers wrote. SOURCE: The study was led by Matthieu Legrand, MD, PhD, of the Department of Anesthesia and Perioperative Care at the University of California, San Francisco. It was published online on June 25 in JAMA Cardiology. LIMITATIONS: The researchers acknowledged several limitations of the research, including how the sample size may have limited the ability to detect complications with small effects in subpopulations. The absence of systematic postoperative troponin measurements also reduced sensitivity in detecting myocardial injury. DISCLOSURES: Several of the authors disclosed receiving grants from the National Institutes of Health, the Department of Defense, Edwards Lifesciences, Nordic Pharma, and others. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
